Formalin-fixed, paraffin-embedded human Bladder Carcinoma stained with Cytokeratin 19 Monoclonal Antibody (SPM561)
Flow Cytometric Analysis of MeOH-fixed MCF-7 cells using Cytokeratin 19 Monoclonal Antibody (SPM561) followed by Goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).
Immunofluorescence Analysis of MeOH-fixed MCF-7 cells labeling CK19 using Cytokeratin 19 Mouse Monoclonal Antibody (SPM561) followed by Goat anti-Mouse IgG-CF488 (Green). The nuclear counterstain is Reddot (Red)
Western Blot Analysis of HepG2 cell lysate using Cytokeratin 19 Mouse MAb (SPM561)
This Ab reacts with the rod domain of human cytokeratin 19 (CK19), a polypeptide of 40kDa. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.
